OA11142A - Arylsulfonyl hydroxamic acid derivatives - Google Patents

Arylsulfonyl hydroxamic acid derivatives Download PDF

Info

Publication number: OA11142A
Authority: OA; OAPI
Prior art keywords: aryl; alkyl; heteroaryl; alkoxy; crc6
Prior art date: 1997-02-11

Application number

OA9900174A

Other languages

English (en)

Inventor

Kim Francis Mcclure

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-11

Filing date

1999-08-06

Publication date

2003-04-25

1999-08-06 Application filed by Pfizer filed Critical Pfizer

2003-04-25 Publication of OA11142A publication Critical patent/OA11142A/en

Links

-1 Arylsulfonyl hydroxamic Chemical compound 0.000 title claims abstract description 71
239000002253 acid Substances 0.000 title description 87
150000001875 compounds Chemical class 0.000 claims abstract description 116
238000011282 treatment Methods 0.000 claims abstract description 18
102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 14
108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 14
201000010099 disease Diseases 0.000 claims abstract description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
238000004519 manufacturing process Methods 0.000 claims abstract description 13
230000000694 effects Effects 0.000 claims abstract description 11
206010028980 Neoplasm Diseases 0.000 claims abstract description 9
206010003246 arthritis Diseases 0.000 claims abstract description 8
201000011510 cancer Diseases 0.000 claims abstract description 8
206010040047 Sepsis Diseases 0.000 claims abstract description 7
208000028169 periodontal disease Diseases 0.000 claims abstract description 7
208000030507 AIDS Diseases 0.000 claims abstract description 6
231100000433 cytotoxic Toxicity 0.000 claims abstract description 6
230000001472 cytotoxic effect Effects 0.000 claims abstract description 6
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 6
208000037803 restenosis Diseases 0.000 claims abstract description 6
206010040070 Septic Shock Diseases 0.000 claims abstract description 5
230000036303 septic shock Effects 0.000 claims abstract description 5
206010014989 Epidermolysis bullosa Diseases 0.000 claims abstract description 4
206010039705 Scleritis Diseases 0.000 claims abstract description 4
208000002780 macular degeneration Diseases 0.000 claims abstract description 4
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 4
125000000217 alkyl group Chemical group 0.000 claims description 112
125000003118 aryl group Chemical group 0.000 claims description 98
ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 claims description 91
125000001072 heteroaryl group Chemical group 0.000 claims description 66
125000003545 alkoxy group Chemical group 0.000 claims description 63
239000001257 hydrogen Substances 0.000 claims description 52
229910052739 hydrogen Inorganic materials 0.000 claims description 52
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 48
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 38
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 34
239000001301 oxygen Chemical group 0.000 claims description 34
229910052760 oxygen Inorganic materials 0.000 claims description 34
229910052757 nitrogen Inorganic materials 0.000 claims description 30
229910052799 carbon Inorganic materials 0.000 claims description 29
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 27
102000003390 tumor necrosis factor Human genes 0.000 claims description 27
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 24
125000005842 heteroatom Chemical group 0.000 claims description 24
229910052684 Cerium Inorganic materials 0.000 claims description 23
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 20
125000004104 aryloxy group Chemical group 0.000 claims description 20
229910052717 sulfur Chemical group 0.000 claims description 20
239000011593 sulfur Chemical group 0.000 claims description 20
125000005553 heteroaryloxy group Chemical group 0.000 claims description 19
230000005764 inhibitory process Effects 0.000 claims description 17
238000000034 method Methods 0.000 claims description 16
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 13
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 13
125000001424 substituent group Chemical group 0.000 claims description 12
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 10
125000004568 thiomorpholinyl group Chemical group 0.000 claims description 10
125000004423 acyloxy group Chemical group 0.000 claims description 8
125000005110 aryl thio group Chemical group 0.000 claims description 8
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 7
125000002757 morpholinyl group Chemical group 0.000 claims description 7
241000124008 Mammalia Species 0.000 claims description 6
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 6
125000004193 piperazinyl group Chemical group 0.000 claims description 6
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
125000001769 aryl amino group Chemical group 0.000 claims description 5
125000001309 chloro group Chemical group Cl* 0.000 claims description 5
125000001153 fluoro group Chemical group F* 0.000 claims description 5
125000005241 heteroarylamino group Chemical group 0.000 claims description 5
125000005936 piperidyl group Chemical group 0.000 claims description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
125000005035 acylthio group Chemical group 0.000 claims description 4
239000002246 antineoplastic agent Substances 0.000 claims description 4
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 4
125000003386 piperidinyl group Chemical group 0.000 claims description 4
150000008575 L-amino acids Chemical class 0.000 claims description 3
125000004442 acylamino group Chemical group 0.000 claims description 3
125000003282 alkyl amino group Chemical group 0.000 claims description 3
125000004122 cyclic group Chemical group 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 2
125000000041 C6-C10 aryl group Chemical group 0.000 claims 35
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 13
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 8
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
125000002393 azetidinyl group Chemical group 0.000 claims 7
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
125000004414 alkyl thio group Chemical group 0.000 claims 4
125000005368 heteroarylthio group Chemical group 0.000 claims 4
125000002252 acyl group Chemical group 0.000 claims 3
125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 3
125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 3
125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 2
125000005135 aryl sulfinyl group Chemical group 0.000 claims 2
125000000623 heterocyclic group Chemical group 0.000 claims 2
125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 2
125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 2
CSLDBJUJDSYAKG-FPOVZHCZSA-N (2r,3s)-1-[4-(1,3-benzothiazol-2-ylmethoxy)phenyl]sulfonyl-n,3-dihydroxy-3-methylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@@](C)(O)CCCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=NC2=CC=CC=C2S1 CSLDBJUJDSYAKG-FPOVZHCZSA-N 0.000 claims 1
VFMQGJQJUNCZDG-FPOVZHCZSA-N (2r,3s)-1-[4-[2-(4-fluorophenyl)ethoxy]phenyl]sulfonyl-n,3-dihydroxy-3-methylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@@](C)(O)CCCN1S(=O)(=O)C(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 VFMQGJQJUNCZDG-FPOVZHCZSA-N 0.000 claims 1
UFIPRXRNECOZCM-ZWKOTPCHSA-N (2r,3s)-n,3-dihydroxy-1-(4-phenylmethoxyphenyl)sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@@H](O)CCCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=CC=C1 UFIPRXRNECOZCM-ZWKOTPCHSA-N 0.000 claims 1
LTXMNGNZBGPTLR-LSDHHAIUSA-N (2r,3s)-n,3-dihydroxy-1-[4-(1,3-thiazol-5-ylmethoxy)phenyl]sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@@H](O)CCCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CN=CS1 LTXMNGNZBGPTLR-LSDHHAIUSA-N 0.000 claims 1
UFIMUQYMICWLMR-WCQYABFASA-N (2r,3s)-n,3-dihydroxy-1-[4-(2h-tetrazol-5-ylmethoxy)phenyl]sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@@H](O)CCCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=NN=NN1 UFIMUQYMICWLMR-WCQYABFASA-N 0.000 claims 1
SLKKVBIPVXPLEG-DLBZAZTESA-N (2r,3s)-n,3-dihydroxy-1-[4-(pyridin-4-ylmethoxy)phenyl]sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@@H](O)CCCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=NC=C1 SLKKVBIPVXPLEG-DLBZAZTESA-N 0.000 claims 1
WOQSKGWYPFEBIZ-RDJZCZTQSA-N (2r,3s)-n,3-dihydroxy-3-methyl-1-[4-(1,3-thiazol-5-ylmethoxy)phenyl]sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@@](C)(O)CCCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CN=CS1 WOQSKGWYPFEBIZ-RDJZCZTQSA-N 0.000 claims 1
DOOZILOLHOKUGO-HKUYNNGSSA-N (2r,3s)-n,3-dihydroxy-3-methyl-1-[4-(pyridin-4-ylmethoxy)phenyl]sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@@](C)(O)CCCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=NC=C1 DOOZILOLHOKUGO-HKUYNNGSSA-N 0.000 claims 1
JMBOAEVTEXTTPO-BXUZGUMPSA-N (2r,4r)-1-[3-(4-fluorophenoxy)propylsulfonyl]-2-(hydroxycarbamoyl)piperidine-4-carboxylic acid Chemical compound ONC(=O)[C@H]1C[C@H](C(O)=O)CCN1S(=O)(=O)CCCOC1=CC=C(F)C=C1 JMBOAEVTEXTTPO-BXUZGUMPSA-N 0.000 claims 1
ACEUKQZDNBIUHG-CRAIPNDOSA-N (2r,4r)-n,4-dihydroxy-1-(4-phenylmethoxyphenyl)sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1C[C@H](O)CCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=CC=C1 ACEUKQZDNBIUHG-CRAIPNDOSA-N 0.000 claims 1
KEVSGIPPEHZMGV-OALZAMAHSA-N (2r,4r)-n-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(piperazine-1-carbonyl)piperidine-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1S(=O)(=O)N1[C@@H](C(=O)NO)C[C@H](C(=O)N2CCNCC2)CC1 KEVSGIPPEHZMGV-OALZAMAHSA-N 0.000 claims 1
FCLQINRREQAAHO-MAUKXSAKSA-N (2r,4s)-1-[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl-n,4-dihydroxypiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1C[C@@H](O)CCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=C(F)C=C1 FCLQINRREQAAHO-MAUKXSAKSA-N 0.000 claims 1
ACEUKQZDNBIUHG-MAUKXSAKSA-N (2r,4s)-n,4-dihydroxy-1-(4-phenylmethoxyphenyl)sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1C[C@@H](O)CCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=CC=C1 ACEUKQZDNBIUHG-MAUKXSAKSA-N 0.000 claims 1
UUSUIALWMWHMSS-CRAIPNDOSA-N (2r,5r)-1-[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl-n,5-dihydroxypiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1CC[C@@H](O)CN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=C(F)C=C1 UUSUIALWMWHMSS-CRAIPNDOSA-N 0.000 claims 1
UUSUIALWMWHMSS-MAUKXSAKSA-N (2r,5s)-1-[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl-n,5-dihydroxypiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1CC[C@H](O)CN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=C(F)C=C1 UUSUIALWMWHMSS-MAUKXSAKSA-N 0.000 claims 1
GIGWICZCQGBJDH-MAUKXSAKSA-N (2r,5s)-n,5-dihydroxy-1-(4-phenylmethoxyphenyl)sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1CC[C@H](O)CN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=CC=C1 GIGWICZCQGBJDH-MAUKXSAKSA-N 0.000 claims 1
125000006720 (C1-C6) alkyl (C6-C10) aryl group Chemical group 0.000 claims 1
125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
125000000753 cycloalkyl group Chemical group 0.000 claims 1
WOZBOFIMMNNBIE-LEWJYISDSA-N propan-2-yl n-[(2r,3s)-1-[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl-2-(hydroxycarbamoyl)piperidin-3-yl]carbamate Chemical compound ONC(=O)[C@H]1[C@@H](NC(=O)OC(C)C)CCCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=C(F)C=C1 WOZBOFIMMNNBIE-LEWJYISDSA-N 0.000 claims 1
239000004576 sand Substances 0.000 claims 1
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract description 4
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract description 2
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 abstract description 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract description 2
229930012538 Paclitaxel Natural products 0.000 abstract description 2
229940009456 adriamycin Drugs 0.000 abstract description 2
229930013930 alkaloid Natural products 0.000 abstract description 2
238000002648 combination therapy Methods 0.000 abstract description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract description 2
229940079593 drug Drugs 0.000 abstract description 2
239000003814 drug Substances 0.000 abstract description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract description 2
229960005420 etoposide Drugs 0.000 abstract description 2
229960001592 paclitaxel Drugs 0.000 abstract description 2
229910052697 platinum Inorganic materials 0.000 abstract description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract description 2
229940063683 taxotere Drugs 0.000 abstract description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract description 2
229960004528 vincristine Drugs 0.000 abstract description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract description 2
208000025865 Ulcer Diseases 0.000 abstract 1
229940035676 analgesics Drugs 0.000 abstract 1
239000000730 antalgic agent Substances 0.000 abstract 1
230000036269 ulceration Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 description 53
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 52
239000000243 solution Substances 0.000 description 40
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 37
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
125000006239 protecting group Chemical group 0.000 description 28
238000006243 chemical reaction Methods 0.000 description 27
150000002148 esters Chemical class 0.000 description 23
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 22
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
239000007787 solid Substances 0.000 description 19
229940093499 ethyl acetate Drugs 0.000 description 17
235000019439 ethyl acetate Nutrition 0.000 description 17
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
238000003556 assay Methods 0.000 description 14
239000012267 brine Substances 0.000 description 14
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 12
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
238000001914 filtration Methods 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
238000007792 addition Methods 0.000 description 11
239000003112 inhibitor Substances 0.000 description 11
229940073584 methylene chloride Drugs 0.000 description 11
239000000758 substrate Substances 0.000 description 11
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
239000000706 filtrate Substances 0.000 description 10
229960003010 sodium sulfate Drugs 0.000 description 10
229910052938 sodium sulfate Inorganic materials 0.000 description 10
235000011152 sodium sulphate Nutrition 0.000 description 10
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
102000004142 Trypsin Human genes 0.000 description 9
108090000631 Trypsin Proteins 0.000 description 9
229960004132 diethyl ether Drugs 0.000 description 9
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
239000012588 trypsin Substances 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
239000006260 foam Substances 0.000 description 8
239000012044 organic layer Substances 0.000 description 8
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 7
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 7
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
239000007983 Tris buffer Substances 0.000 description 7
239000012131 assay buffer Substances 0.000 description 7
238000003818 flash chromatography Methods 0.000 description 7
235000011167 hydrochloric acid Nutrition 0.000 description 7
229960000443 hydrochloric acid Drugs 0.000 description 7
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 5
239000004677 Nylon Substances 0.000 description 5
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
229960000583 acetic acid Drugs 0.000 description 5
235000011054 acetic acid Nutrition 0.000 description 5
UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
239000000284 extract Substances 0.000 description 5
239000010410 layer Substances 0.000 description 5
229910052744 lithium Inorganic materials 0.000 description 5
229920001778 nylon Polymers 0.000 description 5
238000000746 purification Methods 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
238000010992 reflux Methods 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
239000011734 sodium Substances 0.000 description 5
108091007196 stromelysin Proteins 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
239000000010 aprotic solvent Substances 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
238000010828 elution Methods 0.000 description 4
238000005227 gel permeation chromatography Methods 0.000 description 4
150000002431 hydrogen Chemical class 0.000 description 4
150000002466 imines Chemical class 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
229960001040 ammonium chloride Drugs 0.000 description 3
235000019270 ammonium chloride Nutrition 0.000 description 3
238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
230000005284 excitation Effects 0.000 description 3
238000007327 hydrogenolysis reaction Methods 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
150000004702 methyl esters Chemical class 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
239000002904 solvent Substances 0.000 description 3
XAFKOOKIABRJOO-YRZWDFBDSA-N (2R,4S)-6-methoxypiperidine-1,2,4-tricarboxylic acid Chemical compound COC1C[C@@H](C(O)=O)C[C@H](C(O)=O)N1C(O)=O XAFKOOKIABRJOO-YRZWDFBDSA-N 0.000 description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
GVJJIQVNWOGRNL-UHFFFAOYSA-N 3-(4-fluorophenoxy)propane-1-sulfonyl chloride Chemical compound FC1=CC=C(OCCCS(Cl)(=O)=O)C=C1 GVJJIQVNWOGRNL-UHFFFAOYSA-N 0.000 description 2
NCQJBPXXRXOIJD-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C(CC(O)=O)NC(=O)OC(C)(C)C)=CC=C21 NCQJBPXXRXOIJD-UHFFFAOYSA-N 0.000 description 2
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
102100027995 Collagenase 3 Human genes 0.000 description 2
108050005238 Collagenase 3 Proteins 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
241000282412 Homo Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
239000011575 calcium Chemical group 0.000 description 2
229910052791 calcium Chemical group 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000012043 crude product Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000004210 ether based solvent Substances 0.000 description 2
PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
239000007789 gas Substances 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 2
XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 2
239000013641 positive control Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000006268 reductive amination reaction Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
238000007127 saponification reaction Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000011877 solvent mixture Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000006277 sulfonation reaction Methods 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
DCFFLPZTPOUVNG-QGZVFWFLSA-N (2r)-1-[4-[(2-chloro-1,3-thiazol-5-yl)methoxy]phenyl]sulfonyl-n-hydroxy-2-methyl-3-oxopiperidine-2-carboxamide Chemical compound C1CCC(=O)[C@](C)(C(=O)NO)N1S(=O)(=O)C(C=C1)=CC=C1OCC1=CN=C(Cl)S1 DCFFLPZTPOUVNG-QGZVFWFLSA-N 0.000 description 1
BPKRXVSGFOQYKM-HXUWFJFHSA-N (2r)-1-[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl-n-hydroxy-2-methyl-3-oxopiperidine-2-carboxamide Chemical compound C1CCC(=O)[C@](C)(C(=O)NO)N1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=C(F)C=C1 BPKRXVSGFOQYKM-HXUWFJFHSA-N 0.000 description 1
JDVKIBANBGATGZ-ZWNOBZJWSA-N (2r,4r)-4-methoxycarbonyl-1-(4-methoxyphenyl)sulfonylpiperidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1C[C@H](C(=O)OC)CCN1S(=O)(=O)C1=CC=C(OC)C=C1 JDVKIBANBGATGZ-ZWNOBZJWSA-N 0.000 description 1
125000006545 (C1-C9) alkyl group Chemical group 0.000 description 1
125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 description 1
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
FUGFMGKHXKOFDJ-UHFFFAOYSA-N 2,2-dimethylthiomorpholine Chemical compound CC1(C)CNCCS1 FUGFMGKHXKOFDJ-UHFFFAOYSA-N 0.000 description 1
MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
WLRPOFUYNOUDRF-RKDXNWHRSA-N 2-o-tert-butyl 4-o-methyl (2r,4r)-piperidine-2,4-dicarboxylate Chemical compound COC(=O)[C@@H]1CCN[C@@H](C(=O)OC(C)(C)C)C1 WLRPOFUYNOUDRF-RKDXNWHRSA-N 0.000 description 1
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
OFUIRQMRJHLJCI-UHFFFAOYSA-N 4-[(4-fluorophenyl)methoxy]benzenesulfonic acid;sodium Chemical compound [Na].C1=CC(S(=O)(=O)O)=CC=C1OCC1=CC=C(F)C=C1 OFUIRQMRJHLJCI-UHFFFAOYSA-N 0.000 description 1
RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
ULUPAWKAWBVCAI-UHFFFAOYSA-N 4-hydroxybenzenesulfonic acid;sodium Chemical compound [Na].OC1=CC=C(S(O)(=O)=O)C=C1 ULUPAWKAWBVCAI-UHFFFAOYSA-N 0.000 description 1
DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
229910014585 C2-Ce Inorganic materials 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical group [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
238000005821 Claisen rearrangement reaction Methods 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
102100029692 Matrix metalloproteinase-21 Human genes 0.000 description 1
101710082411 Matrix metalloproteinase-21 Proteins 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000002102 aryl alkyloxo group Chemical group 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
229910052804 chromium Chemical group 0.000 description 1
239000011651 chromium Chemical group 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Chemical group 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
229960002433 cysteine Drugs 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
FXORZKOZOQWVMQ-UHFFFAOYSA-L dichloropalladium;triphenylphosphane Chemical compound Cl[Pd]Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 FXORZKOZOQWVMQ-UHFFFAOYSA-L 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
238000007273 lactonization reaction Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000018977 lysine Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
KEGNZGJOLHOINE-IUODEOHRSA-N methyl (2r,4r)-1-[3-(4-fluorophenoxy)propylsulfonyl]-2-(hydroxycarbamoyl)piperidine-4-carboxylate Chemical compound ONC(=O)[C@H]1C[C@H](C(=O)OC)CCN1S(=O)(=O)CCCOC1=CC=C(F)C=C1 KEGNZGJOLHOINE-IUODEOHRSA-N 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
229960002429 proline Drugs 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
238000010791 quenching Methods 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229960001153 serine Drugs 0.000 description 1
230000035939 shock Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
239000000725 suspension Substances 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
GINSRDSEEGBTJO-UHFFFAOYSA-N thietane 1-oxide Chemical compound O=S1CCC1 GINSRDSEEGBTJO-UHFFFAOYSA-N 0.000 description 1
125000005505 thiomorpholino group Chemical group 0.000 description 1
229960002898 threonine Drugs 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
DRDCQJADRSJFFD-UHFFFAOYSA-N tris-hydroxymethyl-methyl-ammonium Chemical class OC[N+](C)(CO)CO DRDCQJADRSJFFD-UHFFFAOYSA-N 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1
229960004441 tyrosine Drugs 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
AIDS & HIV (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Tropical Medicine & Parasitology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Hydrogenated Pyridines (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

OA9900174A 1997-02-11 1999-08-06 Arylsulfonyl hydroxamic acid derivatives OA11142A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US3760097P	1997-02-11	1997-02-11

Publications (1)

Publication Number	Publication Date
OA11142A true OA11142A (en)	2003-04-25

Family

ID=21895216

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9900174A OA11142A (en)	1997-02-11	1999-08-06	Arylsulfonyl hydroxamic acid derivatives

Country Status (37)

Country	Link
US (1)	US6599890B1 (fr)
EP (1)	EP0960098A1 (fr)
JP (1)	JP3710489B2 (fr)
KR (1)	KR20000070923A (fr)
CN (1)	CN1247531A (fr)
AP (1)	AP958A (fr)
AR (1)	AR011123A1 (fr)
AU (1)	AU722784B2 (fr)
BG (1)	BG63430B1 (fr)
BR (1)	BR9807678A (fr)
CA (1)	CA2280151C (fr)
CO (1)	CO4950619A1 (fr)
DZ (1)	DZ2416A1 (fr)
EA (1)	EA002546B1 (fr)
GT (1)	GT199800026A (fr)
HN (1)	HN1998000020A (fr)
HR (1)	HRP980070B1 (fr)
HU (1)	HUP0000657A3 (fr)
ID (1)	ID22809A (fr)
IL (1)	IL131123A0 (fr)
IS (1)	IS5130A (fr)
MA (1)	MA24469A1 (fr)
NO (1)	NO993836L (fr)
NZ (1)	NZ336836A (fr)
OA (1)	OA11142A (fr)
PA (1)	PA8446101A1 (fr)
PE (1)	PE58699A1 (fr)
PL (1)	PL334997A1 (fr)
SA (1)	SA98180856A (fr)
SK (1)	SK101399A3 (fr)
TN (1)	TNSN98025A1 (fr)
TR (1)	TR199901926T2 (fr)
TW (1)	TW502020B (fr)
UY (1)	UY24880A1 (fr)
WO (1)	WO1998034918A1 (fr)
YU (1)	YU37499A (fr)
ZA (1)	ZA981061B (fr)

Families Citing this family (328)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ336836A (en) *	1997-02-11	2001-02-23	Pfizer	Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
BR9910678A (pt)	1998-05-14	2001-10-02	Du Pont Pharm Co	Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto
UA59453C2 (uk) *	1998-08-12	2003-09-15	Пфайзер Продактс Інк.	Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
WO2000009492A1 (fr) *	1998-08-12	2000-02-24	Pfizer Products Inc.	Inhibiteurs de l'enzyme de conversion du facteur de necrose tumorale alpha (tace)
AU6228499A (en) *	1998-10-22	2000-05-08	Akzo Nobel N.V.	Tetrahydropyridopyridine derivatives and intermediates for producing the same
US6753337B2 (en)	1999-01-27	2004-06-22	Wyeth Holdings Corporation	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6326516B1 (en)	1999-01-27	2001-12-04	American Cyanamid Company	Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6946473B2 (en)	1999-01-27	2005-09-20	Wyeth Holdings Corporation	Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6277885B1 (en)	1999-01-27	2001-08-21	American Cyanamid Company	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en)	1999-01-27	2001-11-06	American Cyanamid Company	Acetylenic sulfonamide thiol tace inhibitors
US6340691B1 (en)	1999-01-27	2002-01-22	American Cyanamid Company	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6225311B1 (en)	1999-01-27	2001-05-01	American Cyanamid Company	Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6200996B1 (en)	1999-01-27	2001-03-13	American Cyanamid Company	Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
BR0007784A (pt)	1999-01-27	2002-02-05	American Cyanamid Co	Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
US6762178B2 (en)	1999-01-27	2004-07-13	Wyeth Holdings Corporation	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
EP1081137A1 (fr) *	1999-08-12	2001-03-07	Pfizer Products Inc.	Inhibiteurs sélectifs de l'aggrécanase pour le traitement de l'ostéoarthrite
UA74803C2 (uk)	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6462063B1 (en)	2000-02-04	2002-10-08	Fibrogen, Inc.	C-proteinase inhibitors
US6458822B2 (en)	2000-03-13	2002-10-01	Pfizer Inc.	2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
EP1138680A1 (fr) *	2000-03-29	2001-10-04	Pfizer Products Inc.	Acides gem-substitués alpha-sulfonylamino hydroxamiques comme inhibiteurs de métalloprotease
GB0011409D0 (en) *	2000-05-11	2000-06-28	Smithkline Beecham Plc	Novel compounds
JP2001322977A (ja) *	2000-05-12	2001-11-20	Kotobuki Seiyaku Kk	ピペコリン酸誘導体及びその製造方法並びにこれを含有する医薬組成物
NZ527302A (en)	2001-01-05	2006-10-27	Abgenix Inc	Antibodies to insulin-like growth factor I receptor
MXPA01013326A (es) *	2001-02-14	2002-08-26	Warner Lambert Co	Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
MXPA01013171A (es)	2001-02-14	2004-05-21	Warner Lambert Co	Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz.
MXPA01013172A (es) *	2001-02-14	2002-08-21	Warner Lambert Co	Inhibidores sulfonamida de metaloproteinasa de matriz.
WO2003000194A2 (fr)	2001-06-21	2003-01-03	Pfizer Inc.	Derives bicycliques de pyridine et de pyrimidine utiles en tant qu'agents anticancereux
AUPR726201A0 (en) *	2001-08-24	2001-09-20	Fujisawa Pharmaceutical Co., Ltd.	New use of a cyclic compound
JP2005507937A (ja)	2001-11-01	2005-03-24	ワイス・ホールディングズ・コーポレイション	マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
MXPA04008403A (es)	2002-03-01	2004-11-26	Pfizer	Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso.
SG2013013339A (en)	2002-03-13	2014-12-30	Array Biopharma Inc	N3 alkylated benzimidazole derivatives as mek inhibitors
AU2003237532B2 (en)	2002-06-12	2009-07-30	Symphony Evolution, Inc.	Human ADAM-10 inhibitors
UA77303C2 (en)	2002-06-14	2006-11-15	Pfizer	Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
AU2003286321A1 (en)	2002-12-19	2004-07-14	Pfizer Inc.	2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
US7199155B2 (en)	2002-12-23	2007-04-03	Wyeth Holdings Corporation	Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
PT2476667E (pt)	2003-02-26	2014-09-18	Sugen Inc	Compostos de aminoheteroarilo como inibidores da proteína quinase
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
WO2005021554A1 (fr)	2003-08-29	2005-03-10	Pfizer Inc.	Thienopyridine-phenylacetamides et leurs derives utiles comme nouveaux agents anti-angiogeniques
US7144907B2 (en)	2003-09-03	2006-12-05	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
KR101190912B1 (ko)	2003-11-19	2012-10-12	어레이 바이오파마 인크.	Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
GT200500139A (es)	2004-06-08	2005-07-25		Metodo para la preparacion de acidos hidroxamicos
CN101014365B (zh)	2004-07-16	2011-04-13	辉瑞产品公司	使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
JP4242911B2 (ja)	2004-08-26	2009-03-25	ファイザー・インク	プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
MY146381A (en)	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7429667B2 (en)	2005-01-20	2008-09-30	Ardea Biosciences, Inc.	Phenylamino isothiazole carboxamidines as MEK inhibitors
TWI441637B (zh)	2005-05-18	2014-06-21	Array Biopharma Inc	Ｍｅｋ雜環抑制劑及其使用方法
US8101799B2 (en)	2005-07-21	2012-01-24	Ardea Biosciences	Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
AU2006292278B2 (en)	2005-09-20	2012-03-08	Osi Pharmaceuticals, Inc.	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TWI405756B (zh)	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
US7842836B2 (en)	2006-04-11	2010-11-30	Ardea Biosciences	N-aryl-N'alkyl sulfamides as MEK inhibitors
AU2007237901B2 (en)	2006-04-18	2012-07-05	Ardea Biosciences, Inc.	Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors
WO2008075196A1 (fr)	2006-12-15	2008-06-26	Pfizer Products Inc.	Dérivés du benzamidazole
ES2547303T3 (es)	2007-01-19	2015-10-05	Ardea Biosciences, Inc.	Inhibidores de MEK
DK2146779T3 (en)	2007-04-18	2016-11-28	Pfizer Prod Inc	Sulfonylamid derivatives to treat abnormal cell growth.
US8530463B2 (en)	2007-05-07	2013-09-10	Hale Biopharma Ventures Llc	Multimodal particulate formulations
CA2694646C (fr)	2007-07-30	2017-09-05	Ardea Biosciences, Inc.	Combinaisons d'inhibiteurs de mek et d'inhibiteurs de raf kinase et leurs utilisations
TWI441820B (zh)	2007-12-19	2014-06-21	Genentech Inc	５－苯胺咪唑并吡啶及使用方法
BRPI0906473A8 (pt)	2008-01-04	2016-02-10	Intellikine Inc	Certas entidades químicas, composições e métodos
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009114870A2 (fr)	2008-03-14	2009-09-17	Intellikine, Inc.	Inhibiteurs de kinases, et procédés d’utilisation associés
US20090258865A1 (en)	2008-03-28	2009-10-15	Hale Biopharma Ventures, Llc	Administration of benzodiazepine compositions
MX2011000216A (es)	2008-07-08	2011-03-29	Intellikine Inc	Inhibidores de cinasa y metodos para su uso.
CA2737597C (fr)	2008-10-16	2017-03-14	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Anticorps entierement humains diriges contre un antigene associe au melanome de masse moleculaire elevee et leurs utilisations
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
CA3014224C (fr)	2009-02-05	2022-05-24	Immunogen, Inc.	Derives de benzodiazepine-indoline et procedes de preparation des derives
SG172857A1 (en)	2009-02-09	2011-08-29	Supergen Inc	Pyrrolopyrimidinyl axl kinase inhibitors
US20120189641A1 (en)	2009-02-25	2012-07-26	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
US20110171124A1 (en)	2009-02-26	2011-07-14	Osi Pharmaceuticals, Inc.	In situ methods for monitoring the EMT status of tumor cells in vivo
WO2010098866A1 (fr)	2009-02-27	2010-09-02	Supergen, Inc.	Inhibiteurs cyclopentathiophène/cyclohexathiophène de l'adn méthyltransférase
US8642834B2 (en)	2009-02-27	2014-02-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (fr)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
US8673919B2 (en)	2009-03-27	2014-03-18	Ardea Biosciences, Inc.	Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors
JP5789252B2 (ja)	2009-05-07	2015-10-07	インテリカイン，エルエルシー	複素環式化合物およびその使用
WO2011014726A1 (fr)	2009-07-31	2011-02-03	Osi Pharmaceuticals, Inc.	Polythérapie par inhibiteur de mtor et inhibiteur de langiogenèse
UA111579C2 (uk)	2009-08-17	2016-05-25	Інтеллікіне Ллк	ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
US20120157471A1 (en)	2009-09-01	2012-06-21	Pfizer Inc.	Benzimidazole derivatives
CA2814617C (fr)	2009-10-13	2017-12-19	Allostem Therapeutics Llc	Nouveaux inhibiteurs de mek, utiles dans le traitement des maladies
WO2011049625A1 (fr)	2009-10-20	2011-04-28	Mansour Samadpour	Procédé de criblage d'aflatoxine dans des produits
LT2496567T (lt)	2009-11-05	2017-11-27	Rhizen Pharmaceuticals S.A.	Nauji benzopirano kinazės moduliatoriai
AR080154A1 (es)	2010-02-10	2012-03-14	Immunogen Inc	Anticuerpos cd20 y su utilizacion
ES2607806T5 (es)	2010-02-12	2024-10-07	Pfizer	Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
AU2011223643A1 (en)	2010-03-03	2012-06-28	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223655A1 (en)	2010-03-03	2012-06-28	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP5960688B2 (ja)	2010-05-17	2016-08-02	インコゼンセラピューティクスプライベートリミテッド	プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
JP5951600B2 (ja)	2010-05-21	2016-07-13	インフィニティーファーマシューティカルズ，インコーポレイテッド	キナーゼ調節のための、化合物、組成物および方法
CN103068851B (zh)	2010-06-16	2015-03-11	高等教育联邦系统-匹兹堡大学	内质蛋白的抗体及其用途
US9056865B2 (en)	2010-10-20	2015-06-16	Pfizer Inc.	Pyridine-2-derivatives as smoothened receptor modulators
WO2012064973A2 (fr)	2010-11-10	2012-05-18	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et utilisations de ceux-ci
EP3238722B1 (fr)	2011-01-10	2019-03-13	Infinity Pharmaceuticals, Inc.	Formes solides d'isoquinolinones
WO2012106556A2 (fr)	2011-02-02	2012-08-09	Amgen Inc.	Méthodes et compositions associées à l'inhibition d'igf-1r
SI2675480T1 (sl)	2011-02-15	2019-05-31	Immunogen, Inc.	Metode priprave konjugatov
WO2012116040A1 (fr)	2011-02-22	2012-08-30	OSI Pharmaceuticals, LLC	Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de la kinase du récepteur du facteur de croissance 1 analogue à l'insuline dans le carcinome hépatocellulaire
WO2012116237A2 (fr)	2011-02-23	2012-08-30	Intellikine, Llc	Composés hétérocycliques et leurs utilisations
WO2012142164A1 (fr)	2011-04-12	2012-10-18	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Anticorps monoclonaux humains qui se lient aux facteurs de croissance insulinomimétique (igf) de type i et ii
US20140178368A1 (en)	2011-04-19	2014-06-26	Leslie Lynne SHARP	Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
JP2014519813A (ja)	2011-04-25	2014-08-21	オーエスアイ・ファーマシューティカルズ，エルエルシー	癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
PT2705029T (pt)	2011-05-04	2019-02-01	Rhizen Pharmaceuticals S A	Novos compostos como moduladores de proteína quinases
PT3415139T (pt)	2011-06-14	2022-06-20	Neurelis Inc	Administração de benzodiazepina
EP2734520B1 (fr)	2011-07-19	2016-09-14	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
US9056877B2 (en)	2011-07-19	2015-06-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
DK2734205T3 (en)	2011-07-21	2018-06-14	Tolero Pharmaceuticals Inc	Heterocyclic Protein Kinase Inhibitors
PE20141371A1 (es)	2011-08-29	2014-10-13	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos
MD20140023A2 (ro)	2011-09-22	2014-06-30	Pfizer Inc.	Derivaţi de pirolpirimidină şi purină
US9630979B2 (en)	2011-09-29	2017-04-25	Infinity Pharmaceuticals, Inc.	Inhibitors of monoacylglycerol lipase and methods of their use
CN103998435A (zh) *	2011-10-04	2014-08-20	法国国家健康医疗研究院	新型细胞凋亡诱导化合物
ES2654160T3 (es)	2011-10-04	2018-02-12	Igem Therapeutics Limited	Anticuerpos de IgE anti-HMW-MAA
MX2014005570A (es)	2011-11-08	2014-05-30	Pfizer	El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios.
US9452215B2 (en)	2012-02-22	2016-09-27	The Regents Of The University Of Colorado	Bourvadin derivatives and therapeutic uses thereof
WO2013126617A1 (fr)	2012-02-22	2013-08-29	The Regents Of The University Of Colorado, A Body Corporate	Dérivés de bouvardine et leurs utilisations thérapeutiques
CN104321322A (zh)	2012-03-30	2015-01-28	理森制药股份公司	作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
WO2013152252A1 (fr)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Polythérapie antinéoplasique
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US9738724B2 (en)	2012-06-08	2017-08-22	Sutro Biopharma, Inc.	Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3135690A1 (fr)	2012-06-26	2017-03-01	Sutro Biopharma, Inc.	Proteines fc modifiees contenant des residus specifiques d'acides amines non naturels, leurs conjugues, leurs procedes de preparation et leurs procedes d'utilisation
HK1211208A1 (zh)	2012-08-22	2016-05-20	Immunogen, Inc.	細胞毒性苯並二氮呯衍生物
SI2890402T1 (sl)	2012-08-31	2019-07-31	Sutro Biopharma, Inc.	Modificirane aminokisline vsebujoče acido skupino
EP2909181B1 (fr)	2012-10-16	2017-08-09	Tolero Pharmaceuticals, Inc.	Modulateurs de pkm2 et procédés pour les utiliser
RU2702908C2 (ru)	2012-11-01	2019-10-14	Инфинити Фармасьютикалз, Инк.	Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
HK1219422A1 (zh)	2013-02-28	2017-04-07	Immunogen, Inc.	包含细胞结合剂及细胞毒素剂的轭合物
HK1219423A1 (zh)	2013-02-28	2017-04-07	Immunogen, Inc.	包含细胞结合剂及细胞毒素剂的轭合物
PT2970205T (pt)	2013-03-14	2019-08-26	Tolero Pharmaceuticals Inc	Inibidores da jak2 e da alk2 e métodos para a sua utilização
NZ629037A (en)	2013-03-15	2017-04-28	Infinity Pharmaceuticals Inc	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
HK1219421A1 (zh)	2013-03-15	2017-04-07	因特利凯有限责任公司	激酶抑制剂的组合及其用途
TW201524952A (zh)	2013-03-15	2015-07-01	Araxes Pharma Llc	Ｋｒａｓｇ１２ｃ之共價抑制劑
WO2014143659A1 (fr)	2013-03-15	2014-09-18	Araxes Pharma Llc	Inhibiteurs covalents irréversibles de la gtpase k-ras g12c
US9227978B2 (en)	2013-03-15	2016-01-05	Araxes Pharma Llc	Covalent inhibitors of Kras G12C
KR20160013204A (ko)	2013-05-30	2016-02-03	인피니티 파마슈티칼스, 인코포레이티드	Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
WO2014194030A2 (fr)	2013-05-31	2014-12-04	Immunogen, Inc.	Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
WO2015006555A2 (fr)	2013-07-10	2015-01-15	Sutro Biopharma, Inc.	Anticorps comprenant plusieurs résidus d'acides aminés non naturels site-spécifiques, des procédés permettant leur préparation et leurs méthodes d'utilisation
SI3052096T1 (en)	2013-10-03	2018-04-30	Kura Oncology, Inc.	EAQ inhibitors and application procedures
EP3964507A1 (fr)	2013-10-04	2022-03-09	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
WO2015051241A1 (fr)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
MX380928B (es)	2013-10-10	2025-03-12	Araxes Pharma Llc	Inhibidores de kras g12c.
TWI659021B (zh)	2013-10-10	2019-05-11	亞瑞克西斯製藥公司	Ｋｒａｓｇ１２ｃ之抑制劑
WO2015054658A1 (fr)	2013-10-11	2015-04-16	Sutro Biopharma, Inc.	Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
US20160244452A1 (en)	2013-10-21	2016-08-25	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
UA115388C2 (uk)	2013-11-21	2017-10-25	Пфайзер Інк.	2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (fr)	2014-04-10	2015-10-15	Pfizer Inc.	Dérivés de dihydropyrrolopyrimidine
WO2015168079A1 (fr)	2014-04-29	2015-11-05	Infinity Pharmaceuticals, Inc.	Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k
HRP20192056T1 (hr)	2014-04-30	2020-02-21	Pfizer Inc.	Derivati diheterocikla vezani na cikloalkil
CA2949793C (fr)	2014-06-19	2024-02-27	Ariad Pharmaceuticals, Inc.	Composes heteroaryle d'inhibition de la kinase
WO2016001789A1 (fr)	2014-06-30	2016-01-07	Pfizer Inc.	Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer
EP3177320B1 (fr)	2014-07-31	2021-01-06	The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services	Anticorps monoclonaux humains dirigés contre l'epha4 et leur utilisation
JO3556B1 (ar)	2014-09-18	2020-07-05	Araxes Pharma Llc	علاجات مدمجة لمعالجة السرطان
US10011600B2 (en)	2014-09-25	2018-07-03	Araxes Pharma Llc	Methods and compositions for inhibition of Ras
US9862701B2 (en)	2014-09-25	2018-01-09	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
WO2016097918A1 (fr)	2014-12-18	2016-06-23	Pfizer Inc.	Dérivés de pyrimidine et de triazine, et leur utilisation comme inhibiteurs d'axl
AU2016245864C1 (en)	2015-04-10	2021-09-09	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use thereof
ES2856880T3 (es)	2015-04-15	2021-09-28	Araxes Pharma Llc	Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
AU2016252609B2 (en)	2015-04-20	2022-06-30	Sumitomo Pharma Oncology, Inc.	Predicting response to alvocidib by mitochondrial profiling
CN107709344B (zh)	2015-05-01	2022-07-15	共晶制药股份有限公司	用于治疗黄病毒科病毒和癌症的核苷类似物
HUE045585T2 (hu)	2015-05-18	2020-01-28	Tolero Pharmaceuticals Inc	Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok
TWI703150B (zh)	2015-06-04	2020-09-01	美商庫拉腫瘤技術股份有限公司	用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
WO2017009751A1 (fr)	2015-07-15	2017-01-19	Pfizer Inc.	Dérivés de pyrimidine
US10144724B2 (en)	2015-07-22	2018-12-04	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use thereof
AU2016301315C1 (en)	2015-08-03	2022-07-07	Sumitomo Pharma Oncology, Inc.	Combination therapies for treatment of cancer
CN114230571B (zh)	2015-09-14	2025-07-08	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017058728A1 (fr)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibiteurs de protéines kras portant la mutation g12c
EP3356347A1 (fr)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibiteurs de protéines kras portant la mutation g12c
US10730867B2 (en)	2015-09-28	2020-08-04	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
WO2017058902A1 (fr)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibiteurs de protéines mutantes kras g12c
US10975071B2 (en)	2015-09-28	2021-04-13	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
EP3356359B1 (fr)	2015-09-28	2021-10-20	Araxes Pharma LLC	Inhibiteurs de protéines kras portant la mutation g12c
WO2017058768A1 (fr)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibiteurs de protéines kras portant la mutation g12c
JP2018533939A (ja)	2015-10-19	2018-11-22	アラクセスファーマエルエルシー	Ｒａｓの阻害剤をスクリーニングするための方法
KR102932353B1 (ko)	2015-11-16	2026-02-27	아락세스 파마 엘엘씨	치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
WO2017096165A1 (fr)	2015-12-03	2017-06-08	Agios Pharmaceuticals, Inc.	Inhibiteurs de mat2a pour le traitement du cancer n'exprimant pas mtap
WO2017100546A1 (fr)	2015-12-09	2017-06-15	Araxes Pharma Llc	Procédés de préparation de dérivés de quinazoléine
AU2017212739B2 (en)	2016-01-27	2024-03-21	Sutro Biopharma, Inc.	Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates
US10752639B2 (en)	2016-03-16	2020-08-25	Kura Oncology, Inc.	Bridged bicyclic inhibitors of menin-MLL and methods of use
WO2017161028A1 (fr)	2016-03-16	2017-09-21	Kura Oncology, Inc.	Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
WO2017172979A1 (fr)	2016-03-30	2017-10-05	Araxes Pharma Llc	Composés quinazoline substitués et procédés d'utilisation
CN109414596B (zh)	2016-05-12	2023-09-29	密歇根大学董事会	Ash1l抑制剂和用其进行治疗的方法
WO2017201302A1 (fr)	2016-05-18	2017-11-23	The University Of Chicago	Mutation de btk et résistance à l'ibrutinib
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US10646488B2 (en)	2016-07-13	2020-05-12	Araxes Pharma Llc	Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CA3035081A1 (fr)	2016-09-02	2018-03-08	Dana-Farber Cancer Institute, Inc.	Composition et methodes de traitement des dereglements des lymphocytes b
JP2019529484A (ja)	2016-09-29	2019-10-17	アラクセスファーマエルエルシー	Ｋｒａｓｇ１２ｃ変異体タンパク質の阻害剤
US10377743B2 (en)	2016-10-07	2019-08-13	Araxes Pharma Llc	Inhibitors of RAS and methods of use thereof
WO2018094275A1 (fr)	2016-11-18	2018-05-24	Tolero Pharmaceuticals, Inc.	Promédicaments de l'alvocidib et leur utilisation en tant qu'inhibiteurs de protéines kinases
WO2018098352A2 (fr)	2016-11-22	2018-05-31	Jun Oishi	Ciblage d'expression du point de contrôle immunitaire induit par kras
CA3047557A1 (fr)	2016-12-19	2018-06-28	Tolero Pharmaceuticals, Inc.	Peptides de profilage et procedes de profilage de sensibilite
CR20190338A (es)	2016-12-22	2019-09-09	Amgen Inc	Inhibidores de kras g12c y métodos para su uso
EP3573971A1 (fr)	2017-01-26	2019-12-04	Araxes Pharma LLC	Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer
EP3573954A1 (fr)	2017-01-26	2019-12-04	Araxes Pharma LLC	Composés benzohétéroaromatiques bicycliques fusionnés et leurs procédés d'utilisation
JP7327802B2 (ja)	2017-01-26	2023-08-16	アラクセスファーマエルエルシー	縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
US11136308B2 (en)	2017-01-26	2021-10-05	Araxes Pharma Llc	Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140599A1 (fr)	2017-01-26	2018-08-02	Araxes Pharma Llc	Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation
KR102607101B1 (ko)	2017-01-26	2023-11-29	제트엘아이피 홀딩 리미티드	Cd47 항원 결합 유닛 및 그것의 사용
US20200385364A1 (en)	2017-01-26	2020-12-10	Araxes Pharma Llc	Fused n-heterocyclic compounds and methods of use thereof
CN110691779B (zh)	2017-03-24	2023-10-10	库拉肿瘤学公司	治疗血液系统恶性肿瘤和尤因肉瘤的方法
UA127968C2 (uk)	2017-05-22	2024-02-28	Емджен Інк.	Інгібітори g12c kras і способи їх застосування
CN110869358A (zh)	2017-05-25	2020-03-06	亚瑞克西斯制药公司	Kras的共价抑制剂
TW201906832A (zh)	2017-05-25	2019-02-16	美商亞瑞克西斯製藥公司	用於癌症治療之化合物及其使用方法
WO2018218069A1 (fr)	2017-05-25	2018-11-29	Araxes Pharma Llc	Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants
US11542248B2 (en)	2017-06-08	2023-01-03	Kura Oncology, Inc.	Methods and compositions for inhibiting the interaction of menin with MLL proteins
EP3658588A1 (fr)	2017-07-26	2020-06-03	Sutro Biopharma, Inc.	Méthodes d'utilisation d'anticorps anti-cd74 et de conjugués d'anticorps dans le traitement d'un lymphome à cellules t
US10640504B2 (en)	2017-09-08	2020-05-05	Amgen Inc.	Inhibitors of KRAS G12C and methods of using the same
JP7196160B2 (ja)	2017-09-12	2022-12-26	スミトモファーマオンコロジー，インコーポレイテッド	Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
MA50265A (fr)	2017-09-18	2020-07-29	Sutro Biopharma Inc	Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations
TW201920170A (zh)	2017-09-20	2019-06-01	美商庫拉腫瘤技術股份有限公司	經取代之menin-mll 抑制劑及使用方法
US20200237766A1 (en)	2017-10-13	2020-07-30	Tolero Pharmaceuticals, Inc.	Pkm2 activators in combination with reactive oxygen species for treatment of cancer
US10632209B2 (en)	2017-11-10	2020-04-28	The Regents Of The University Of Michigan	ASH1L inhibitors and methods of treatment therewith
JP7414282B2 (ja)	2017-12-07	2024-01-16	ザリージェンツオブザユニバーシティオブミシガン	Ｎｓｄファミリー阻害物質及びそれによる治療の方法
BR112020020246A8 (pt)	2018-04-05	2022-10-18	Sumitomo Dainippon Pharma Oncology Inc	Inibidores de cinase axl e uso dos mesmos
EP3788053B1 (fr)	2018-05-04	2024-07-10	Amgen Inc.	Inhibiteurs de kras g12c et leurs procédés d'utilisation
MX2020010836A (es)	2018-05-04	2021-01-08	Amgen Inc	Inhibidores de kras g12c y métodos para su uso.
WO2019217691A1 (fr)	2018-05-10	2019-11-14	Amgen Inc.	Inhibiteurs de kras g12c pour le traitement du cancer
WO2019232419A1 (fr)	2018-06-01	2019-12-05	Amgen Inc.	Inhibiteurs de kras g12c et leurs procédés d'utilisation
EP3813784B1 (fr)	2018-06-07	2024-01-10	The Regents Of The University Of Michigan	Inhibiteurs de prc1 et inhibiteurs de prc1 pour leur utilisation dans des méthodes de traitement comprenant ces derniers
AU2019284472B2 (en)	2018-06-11	2024-05-30	Amgen Inc.	KRAS G12C inhibitors for treating cancer
JP7369719B2 (ja)	2018-06-12	2023-10-26	アムジエン・インコーポレーテツド	ＫＲａｓＧ１２Ｃ阻害剤及びそれを使用する方法
KR20210038906A (ko)	2018-07-26	2021-04-08	스미토모 다이니폰 파마 온콜로지, 인크.	비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
BR112021001709A2 (pt)	2018-08-01	2021-05-04	Araxes Pharma Llc	compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
JP2022500454A (ja)	2018-09-17	2022-01-04	ストロバイオファーマインコーポレーテッド	抗葉酸受容体抗体コンジュゲートによる併用療法
AU2019364417A1 (en)	2018-10-24	2021-05-20	Araxes Pharma Llc	2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1H-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of G12C mutant KRAS protein for inhibiting tumor metastasis
JP7516029B2 (ja)	2018-11-16	2024-07-16	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7454572B2 (ja)	2018-11-19	2024-03-22	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤及びその使用方法
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3887373A1 (fr)	2018-11-29	2021-10-06	Araxes Pharma LLC	Composés et procédés d'utilisation associés pour le traitement du cancer
US11034710B2 (en)	2018-12-04	2021-06-15	Sumitomo Dainippon Pharma Oncology, Inc.	CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
AU2019401495B2 (en)	2018-12-20	2025-06-26	Amgen Inc.	Heteroaryl amides useful as KIF18A inhibitors
IL283639B2 (en)	2018-12-20	2024-06-01	Amgen Inc	Kif18a inhibitors
MA54550A (fr)	2018-12-20	2022-03-30	Amgen Inc	Inhibiteurs de kif18a
AU2019404576B2 (en)	2018-12-20	2025-07-17	Amgen Inc.	Heteroaryl amides useful as KIF18A inhibitors
HUE072069T2 (hu)	2019-02-12	2025-10-28	Sumitomo Pharma America Inc	2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
US20230096028A1 (en)	2019-03-01	2023-03-30	Revolution Medicines, Inc.	Bicyclic heterocyclyl compounds and uses thereof
WO2020180768A1 (fr)	2019-03-01	2020-09-10	Revolution Medicines, Inc.	Composés hétéroaryle bicycliques et leurs utilisations
JP2022525149A (ja)	2019-03-20	2022-05-11	スミトモダイニッポンファーマオンコロジー，インコーポレイテッド	ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
AU2020245437A1 (en)	2019-03-22	2021-09-30	Sumitomo Pharma Oncology, Inc.	Compositions comprising PKM2 modulators and methods of treatment using the same
US20220362394A1 (en)	2019-05-03	2022-11-17	Sutro Biopharma, Inc.	Anti-bcma antibody conjugates
EP3738593A1 (fr)	2019-05-14	2020-11-18	Amgen, Inc	Dosage d'inhibiteur de kras pour le traitement de cancers
EP3972973A1 (fr)	2019-05-21	2022-03-30	Amgen Inc.	Formes à l'état solide
AU2020300619A1 (en)	2019-07-03	2022-01-27	Sumitomo Pharma Oncology, Inc.	Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
US20220289724A1 (en)	2019-08-02	2022-09-15	Amgen Inc.	Kif18a inhibitors
JP7699100B2 (ja)	2019-08-02	2025-06-26	アムジエン・インコーポレーテツド	Ｋｉｆ１８ａ阻害剤
AU2020325115B2 (en)	2019-08-02	2026-03-12	Amgen Inc.	Pyridine derivatives as KIF18A inhibitors
MX428368B (es)	2019-08-02	2025-11-13	Amgen Inc	Inhibidores de kif18a
US20220402916A1 (en)	2019-09-18	2022-12-22	Merck Sharp & Dohme Corp.	Small molecule inhibitors of kras g12c mutant
TW202126636A (zh)	2019-09-30	2021-07-16	美商阿吉歐斯製藥公司	作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物
AU2020369569B2 (en)	2019-10-24	2026-06-18	Amgen Inc.	Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
MD4051678T2 (en)	2019-10-28	2026-07-31	Merck Sharp & Dohme Llc	Small molecule inhibitors of the KRAS G12C mutant
WO2021085653A1 (fr)	2019-10-31	2021-05-06	Taiho Pharmaceutical Co., Ltd.	Dérivés de 4-aminobut-2-enamide et sels de ces derniers
CN121471132A (zh)	2019-11-04	2026-02-06	锐新医药公司	Ras抑制剂
WO2021091956A1 (fr)	2019-11-04	2021-05-14	Revolution Medicines, Inc.	Inhibiteurs de ras
MX2022005359A (es)	2019-11-04	2022-06-02	Revolution Medicines Inc	Inhibidores de ras.
PH12022551102A1 (en)	2019-11-08	2023-11-20	Revolution Medicines Inc	Bicyclic heteroaryl compounds and uses thereof
EP4700030A3 (fr)	2019-11-14	2026-03-18	Amgen, Inc.	Synthèse améliorée d'un composé inhibiteur de kras g12c
CA3161156A1 (fr)	2019-11-14	2021-05-20	Amgen Inc.	Synthese amelioree de composes inhibiteurs de kras g12c
CN114980976A (zh)	2019-11-27	2022-08-30	锐新医药公司	共价ras抑制剂及其用途
WO2021106231A1 (fr)	2019-11-29	2021-06-03	Taiho Pharmaceutical Co., Ltd.	Composé ayant une activité inhibitrice contre la mutation kras g12d
CA3163703A1 (fr)	2020-01-07	2021-07-15	Steve Kelsey	Dosage d'inhibiteurs de shp2 et methodes de traitement du cancer
CN115151533B (zh)	2020-01-10	2025-08-08	医疗免疫工程公司	Mek抑制剂及其治疗用途
WO2021155006A1 (fr)	2020-01-31	2021-08-05	Les Laboratoires Servier Sas	Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations
US20230095053A1 (en)	2020-03-03	2023-03-30	Sutro Biopharma, Inc.	Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
TW202204334A (zh)	2020-04-08	2022-02-01	美商阿吉歐斯製藥公司	Menin抑制劑及治療癌症之使用方法
WO2021204159A1 (fr)	2020-04-08	2021-10-14	Agios Pharmaceuticals, Inc.	Inhibiteurs de ménine et procédés d'utilisation pour le traitement du cancer
US12702658B2 (en)	2020-04-24	2026-08-11	Taiho Pharmaceutical Co., Ltd.	Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2021215544A1 (fr)	2020-04-24	2021-10-28	Taiho Pharmaceutical Co., Ltd.	Inhibiteurs de protéine kras g12d
CN115916194A (zh)	2020-06-18	2023-04-04	锐新医药公司	用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
CN116113406B (zh)	2020-07-10	2025-08-29	密歇根大学董事会	Gas41抑制剂及其使用方法
TW202216151A (zh)	2020-07-15	2022-05-01	日商大鵬藥品工業股份有限公司	含有使用於腫瘤之治療之嘧啶化合物之組合
EP4185279A4 (fr)	2020-07-24	2024-05-01	Secura Bio, Inc.	Traitement de cancers à l'aide de modulateurs d'isoformes de la pi3-kinase
EP4208261A1 (fr)	2020-09-03	2023-07-12	Revolution Medicines, Inc.	Utilisation d'inhibiteurs de sos1 pour traiter des malignités à mutations de shp2
IL301298A (en)	2020-09-15	2023-05-01	Revolution Medicines Inc	Indole derivatives as RAS inhibitors in cancer therapy
TW202237119A (zh)	2020-12-10	2022-10-01	美商住友製藥腫瘤公司	Ａｌｋ﹘５抑制劑和彼之用途
AU2021409816A1 (en)	2020-12-22	2023-07-06	Qilu Regor Therapeutics Inc.	Sos1 inhibitors and uses thereof
TW202309022A (zh)	2021-04-13	2023-03-01	美商努法倫特公司	用於治療具egfr突變之癌症之胺基取代雜環
CN117396231A (zh)	2021-04-30	2024-01-12	新基公司	使用抗BCMA抗体药物缀合物（ADC）与γ分泌酶抑制剂（GSI）的组合的组合疗法
IL308195A (en)	2021-05-05	2024-01-01	Revolution Medicines Inc	RAS inhibitors for cancer treatment
PE20240088A1 (es)	2021-05-05	2024-01-16	Revolution Medicines Inc	Inhibidores de ras
WO2022235866A1 (fr)	2021-05-05	2022-11-10	Revolution Medicines, Inc.	Inhibiteurs de ras covalents et leurs utilisations
CN117769554A (zh)	2021-05-28	2024-03-26	大鹏药品工业株式会社	Kras突变蛋白的小分子抑制剂
CA3221395A1 (fr)	2021-06-10	2022-12-15	Neurelis, Inc.	Methodes et compositions pour traiter des troubles epileptiques chez des patients pediatriques
WO2023056589A1 (fr)	2021-10-08	2023-04-13	Servier Pharmaceuticals Llc	Inhibiteurs de ménine et procédés d'utilisation pour le traitement du cancer
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
US20240294548A1 (en)	2021-10-12	2024-09-05	Peloton Therapeutics Inc.	Tricyclic sultams and sulfamides as antitumor agents
TW202340214A (zh)	2021-12-17	2023-10-16	美商健臻公司	做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (fr)	2022-02-11	2023-08-16	Genzyme Corporation	Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2
KR20240156373A (ko)	2022-03-07	2024-10-29	암젠 인크	4-메틸-2-프로판-2-일-피리딘-3-카르보니트릴의 제조 방법
WO2023172940A1 (fr)	2022-03-08	2023-09-14	Revolution Medicines, Inc.	Méthodes de traitement du cancer du poumon réfractaire immunitaire
WO2023211812A1 (fr)	2022-04-25	2023-11-02	Nested Therapeutics, Inc.	Dérivés hétérocycliques en tant qu'inhibiteurs de protéine kinase activée par mitogène (mek)
EP4536364A1 (fr)	2022-06-10	2025-04-16	Revolution Medicines, Inc.	Inhibiteurs de ras macrocycliques
IL317782A (en)	2022-06-30	2025-02-01	Sutro Biopharma Inc	Anti-ROR1 antibodies and conjugates thereof, compositions containing anti-ROR1 antibodies or conjugates thereof, and methods for preparing and using anti-ROR1 antibodies and conjugates thereof
EP4551558A2 (fr)	2022-07-08	2025-05-14	Nested Therapeutics, Inc.	Inhibiteurs de protéine kinase activée par mitogène (mek)
IL320217A (en)	2022-10-14	2025-06-01	Black Diamond Therapeutics Inc	Methods for treating cancer using isoquinoline or 6-azaquinoline derivatives
CN121487738A (zh)	2023-03-30	2026-02-06	锐新医药公司	诱导ras gtp水解的组合物和其用途
WO2024211712A1 (fr)	2023-04-07	2024-10-10	Revolution Medicines, Inc.	Composés macrocycliques condensés en tant qu'inhibiteurs de ras
CN121487951A (zh)	2023-04-07	2026-02-06	锐新医药公司	大环ras抑制剂
EP4695261A1 (fr)	2023-04-14	2026-02-18	Revolution Medicines, Inc.	Formes cristallines d'inhibiteurs de ras, compositions les contenant et leurs procédés d'utilisation
AU2024251341A1 (en)	2023-04-14	2025-10-16	Revolution Medicines, Inc.	Crystalline forms of a ras inhibitor
CN121889153A (zh)	2023-04-24	2026-04-17	耐斯泰德医疗公司	作为促分裂原活化蛋白激酶(mek)抑制剂的杂环衍生物
KR20260019479A (ko)	2023-05-04	2026-02-10	레볼루션 메디슨즈, 인크.	Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh)	2023-08-07	2026-04-17	锐新医药公司	用于治疗ras蛋白相关疾病或病症的rmc-6291
KR20260042550A (ko)	2023-08-24	2026-03-31	다이호야쿠힌고교 가부시키가이샤	세다주리딘 및 아자시티딘의 고정 용량 조합물
AU2024360465A1 (en)	2023-10-12	2026-04-09	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
US12540197B2 (en)	2023-10-13	2026-02-03	Sutro Biopharma, Inc.	Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
KR20260096846A (ko)	2023-10-20	2026-06-24	머크 샤프 앤드 돔 엘엘씨	Kras 단백질의 소분자 억제제
WO2025090905A1 (fr)	2023-10-26	2025-05-01	Nested Therapeutics, Inc.	Formes cristallines de 3-[[3-fluoro-2-(méthylsulfamoylamino)-4-pyridyl]méthyl]-7-[(3-fluoro-2-pyridyl)oxy]-4-méthyl-chromén-2-one
AU2024404879A1 (en)	2023-12-22	2026-06-25	Regor Pharmaceuticals, Inc.	Sos1 inhibitors and uses thereof
WO2025240847A1 (fr)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2025250825A1 (fr)	2024-05-30	2025-12-04	Sutro Biopharma, Inc.	Anticorps anti-trop2, compositions comprenant des anticorps anti-trop2 et méthodes de fabrication et d'utilisation d'anticorps anti-trop2
US20250375445A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025259841A1 (fr)	2024-06-13	2025-12-18	Nested Therapeutics, Inc.	Forme cristalline de 3-[[3-fluoro-2-(méthylsulfamoylamino)-4-pyridyl]méthyl]-7-[(3-fluoro-2-pyridyl)oxy]-4-méthyl-chromén-2-one
WO2025265060A1 (fr)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2026015825A1 (fr)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015790A1 (fr)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015796A1 (fr)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026035750A1 (fr)	2024-08-05	2026-02-12	Pivot Therapeutics, Inc.	Inhibiteurs d'akt et leurs utilisations
WO2026043823A2 (fr)	2024-08-19	2026-02-26	Sutro Biopharma, Inc.	Anticorps comprenant des résidus d'acides aminés non naturels spécifiques à un site, leurs procédés de préparation et leurs utilisations
WO2026050446A1 (fr)	2024-08-29	2026-03-05	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2026072904A2 (fr)	2024-09-26	2026-04-02	Revolution Medicines, Inc.	Compositions et méthodes de traitement du cancer du poumon
WO2026080697A1 (fr)	2024-10-09	2026-04-16	Sutro Biopharma, Inc.	Conjugués d'anticorps à rapports élevés charge utile/anticorps, compositions les comprenant, et leurs procédés d'utilisation
WO2026090116A2 (fr)	2024-10-21	2026-04-30	Revolution Medicines, Inc.	Inhibiteurs de ras
US20260108528A1 (en)	2024-10-22	2026-04-23	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (fr)	2024-10-22	2026-04-30	Revolution Medicines, Inc.	Utilisation d'inhibiteurs ras pour traiter un cancer
WO2026106912A1 (fr)	2024-11-12	2026-05-21	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2026112260A1 (fr)	2024-11-21	2026-05-28	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2026122764A2 (fr)	2024-12-06	2026-06-11	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2026128688A2 (fr)	2024-12-13	2026-06-18	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2026161671A1 (fr)	2025-01-23	2026-07-30	Merck Sharp & Dohme Llc	Inhibiteurs de petites molécules des protéines kras
WO2026161839A1 (fr)	2025-01-27	2026-07-30	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2026165269A1 (fr)	2025-01-29	2026-08-06	Sutro Biopharma, Inc.	Anticorps anti-b7-h3, compositions comprenant des anticorps anti-b7-h3 et procédés de fabrication et méthodes d'utilisation d'anticorps anti-b7-h3

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
CA2218503C (fr) *	1995-04-20	2001-07-24	Pfizer Inc.	Derives d'acide hydroxamique arylsufonyle en tant qu'inhibiteurs de mmp et de tnf
US5753653A (en)	1995-12-08	1998-05-19	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
HUP0000505A3 (en)	1996-08-28	2001-12-28	Procter & Gamble	Saturated 7-9 membered heterocyclic n-hydroxycarboxamide derivatives and pharmaceutical compositions containing them
BR9713465A (pt)	1996-08-28	2000-03-28	Procter & Gamble	Inibidores metalotprotease de amina cìclica sibstituìda
NZ336836A (en) *	1997-02-11	2001-02-23	Pfizer	Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
JPH11199512A (ja) *	1997-10-24	1999-07-27	Pfizer Prod Inc	変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用

1998
- 1998-01-16 NZ NZ336836A patent/NZ336836A/en unknown
- 1998-01-16 SK SK1013-99A patent/SK101399A3/sk unknown
- 1998-01-16 CA CA002280151A patent/CA2280151C/fr not_active Expired - Fee Related
- 1998-01-16 EP EP98900124A patent/EP0960098A1/fr not_active Withdrawn
- 1998-01-16 JP JP53404098A patent/JP3710489B2/ja not_active Expired - Fee Related
- 1998-01-16 CN CN98802460A patent/CN1247531A/zh active Pending
- 1998-01-16 AU AU53366/98A patent/AU722784B2/en not_active Ceased
- 1998-01-16 TR TR1999/01926T patent/TR199901926T2/xx unknown
- 1998-01-16 YU YU37499A patent/YU37499A/sh unknown
- 1998-01-16 ID IDW990847A patent/ID22809A/id unknown
- 1998-01-16 PL PL98334997A patent/PL334997A1/xx unknown
- 1998-01-16 EA EA199900641A patent/EA002546B1/ru not_active IP Right Cessation
- 1998-01-16 BR BR9807678-7A patent/BR9807678A/pt not_active Application Discontinuation
- 1998-01-16 HU HU0000657A patent/HUP0000657A3/hu unknown
- 1998-01-16 WO PCT/IB1998/000064 patent/WO1998034918A1/fr not_active Ceased
- 1998-01-16 IL IL13112398A patent/IL131123A0/xx not_active IP Right Cessation
- 1998-01-16 KR KR1019997007188A patent/KR20000070923A/ko not_active Ceased
- 1998-01-26 HN HN1998000020A patent/HN1998000020A/es unknown
- 1998-02-02 GT GT199800026A patent/GT199800026A/es unknown
- 1998-02-05 AP APAP/P/1998/001179A patent/AP958A/en active
- 1998-02-06 PE PE1998000087A patent/PE58699A1/es not_active Application Discontinuation
- 1998-02-06 UY UY24880A patent/UY24880A1/es not_active IP Right Cessation
- 1998-02-09 TW TW087101709A patent/TW502020B/zh not_active IP Right Cessation
- 1998-02-10 TN TNTNSN98025A patent/TNSN98025A1/fr unknown
- 1998-02-10 ZA ZA9801061A patent/ZA981061B/xx unknown
- 1998-02-10 MA MA24960A patent/MA24469A1/fr unknown
- 1998-02-10 DZ DZ980026A patent/DZ2416A1/fr active
- 1998-02-10 AR ARP980100582A patent/AR011123A1/es not_active Application Discontinuation
- 1998-02-11 CO CO98007136A patent/CO4950619A1/es unknown
- 1998-02-12 HR HR980070A patent/HRP980070B1/xx not_active IP Right Cessation
- 1998-02-15 SA SA98180856A patent/SA98180856A/ar unknown
- 1998-02-18 PA PA19988446101A patent/PA8446101A1/es unknown
1999
- 1999-07-23 IS IS5130A patent/IS5130A/is unknown
- 1999-08-05 BG BG103641A patent/BG63430B1/bg unknown
- 1999-08-06 OA OA9900174A patent/OA11142A/en unknown
- 1999-08-10 NO NO993836A patent/NO993836L/no not_active Application Discontinuation
2000
- 2000-11-08 US US09/708,328 patent/US6599890B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IS5130A (is)	1999-07-23
TNSN98025A1 (fr)	2005-03-15
DZ2416A1 (fr)	2003-01-04
SK101399A3 (en)	2001-09-11
AU722784B2 (en)	2000-08-10
GT199800026A (es)	1999-07-27
US6599890B1 (en)	2003-07-29
CN1247531A (zh)	2000-03-15
EP0960098A1 (fr)	1999-12-01
PL334997A1 (en)	2000-03-27
AU5336698A (en)	1998-08-26
PA8446101A1 (es)	2000-05-24
HUP0000657A3 (en)	2000-10-30
EA002546B1 (ru)	2002-06-27
UY24880A1 (es)	2000-09-29
BG103641A (en)	2000-02-29
HUP0000657A2 (hu)	2000-09-28
CA2280151C (fr)	2005-12-13
JP2000510162A (ja)	2000-08-08
ID22809A (id)	1999-12-09
PE58699A1 (es)	1999-06-21
CA2280151A1 (fr)	1998-08-13
HRP980070A2 (en)	1998-12-31
TR199901926T2 (xx)	1999-12-21
TW502020B (en)	2002-09-11
IL131123A0 (en)	2001-01-28
HN1998000020A (es)	1999-01-08
AP958A (en)	2001-04-17
CO4950619A1 (es)	2000-09-01
WO1998034918A1 (fr)	1998-08-13
EA199900641A1 (ru)	2000-04-24
JP3710489B2 (ja)	2005-10-26
BR9807678A (pt)	2000-02-15
MA24469A1 (fr)	1998-10-01
HRP980070B1 (en)	2002-10-31
ZA981061B (en)	1999-08-10
SA98180856A (ar)	2005-12-03
KR20000070923A (ko)	2000-11-25
YU37499A (sh)	2002-09-19
NO993836L (no)	1999-10-08
NZ336836A (en)	2001-02-23
BG63430B1 (bg)	2002-01-31
NO993836D0 (no)	1999-08-10
AR011123A1 (es)	2000-08-02

Publication	Publication Date	Title
AP958A (en)	2001-04-17	Arylsulfonyl hydroxamic acid derivatives.
AP733A (en)	1999-02-12	Arylsulfonylamino hydroxamic acid derivatives.
OA11081A (en)	2002-03-14	Arylsulfonylamino hydroxamic acid derivatives
RU2146671C1 (ru)	2000-03-20	Производные арилсульфонилгидроксамовой кислоты
IL134300A (en)	2004-07-25	Derivatives of aryloxyacrylylsulfonaminoaminoxamic acid derivatives, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of arthritis, cancer and other diseases characterized by the activity of metalloproteinase-13 of matrix
KR20080109915A (ko)	2008-12-17	유기 화합물
NZ520656A (en)	2004-05-28	Heterocyclic side chain containing metalloprotease inhibitors
GB2321641A (en)	1998-08-05	Amino-sulphonamides as Metalloprotease inhibitors
CA2264044A1 (fr)	1998-03-05	Inhibiteurs de metalloproteases spirocycliques
US6509337B1 (en)	2003-01-21	Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
MXPA99007385A (en)	2000-07-01	Arylsulfonyl hydroxamic acid derivatives
CZ9902833A3 (cs)	2000-10-11	Deriváty arylsulfonylhydroxamových kyselin, farmaceutický prostředek, způsob inhibice matričních metalloproteinas nebo produkce faktoru nekrosy nádorů a způsob léčení
MXPA99001808A (en)	1999-09-20	Arylsulfonylamino hydroxamic acid derivatives
KR100194258B1 (ko)	1999-06-15	아릴설포닐 하이드록삼산 유도체
CZ58999A3 (cs)	2000-03-15	Deriváty arylsulfonylaminohydroxamové kyseliny, farmaceutický prostředek, způsob inhibice matričních metalloproteinas nebo produkce faktoru nekrosy nádorů a způsob léčení